Which brain target eases Parkinson's symptoms best? a Head-to-Head test
NCT ID NCT07745673
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial tests a non-invasive brain stimulation technique called temporal interference stimulation (TIS) in people with Parkinson's disease. It compares two different brain targets—the subthalamic nucleus (STN) and the globus pallidus internus (GPi)—to see which one better improves motor symptoms. Eighteen participants will receive daily 20-minute TIS sessions for a week, with motor function and brain activity measured before and after. The goal is to find out if targeting one area is more effective than the other, which could help refine future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Temporal interference stimulation (TIS) targeting either the subthalamic nucleus (STN) or globus pallidus internus (GPi)
- What this could lead to
- If successful, this could point toward a more effective, non-invasive brain stimulation approach for managing Parkinson's motor symptoms, potentially guiding personalized treatment targets.
- What could go wrong
- This is a small, early exploratory trial with only 18 participants, so results may not be conclusive or generalizable. The stimulation is brief (7 days) and effects may not last. There is also a risk of skin reactions or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongnan Hospital of Wuhan University
RECRUITINGWuhan, Hubei, 430071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.